Status:

UNKNOWN

Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer

Lead Sponsor:

National Cancer Center, Korea

Conditions:

Gastric Cancer

Eligibility:

All Genders

19+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection.

Detailed Description

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection. Actually, if the 14v lymph node metastasis is suspected before surgery, it ...

Eligibility Criteria

Inclusion

  • \<Inclusion Criteria\>
  • Histologically proven primary gastric adenocarcinoma
  • T3N+, T4N+ by CT scan (AJCC 7th classification)
  • Distal margin of gastric cancer Location of distal margin of gastric cancer ; antrum, or angle of the stomach
  • No evidence of other distant metastasis
  • Age ≥ 20 year old
  • Performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
  • No prior treatment of chemotherapy or radiation therapy against any other malignancies, and no prior treatment for gastric cancer including endoscopic mucosal resection
  • Adequate organ functions defined as indicated below:
  • WBC 3000/mm3 - 12,000/mm3
  • \> Serum Hemoglobin 8.0 g/dl
  • \> Serum Platelet 100 000/mm3
  • \< Serum AST 100 IU/l
  • \<Serum ALT 100 IU/l
  • \< Total Bilirubin 2.0 mg/dl
  • Written signed informed consent
  • \<Exclusion Criteria\>
  • Active double cancer (synchronous double cancer and metachronous double cancer within five disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer)
  • Gastric remnant cancer
  • Pregnant or breast-feeding women
  • Mental disorder(diagnosed with mental disorder on medical record)
  • Systemic administration of corticosteroids(include Herbal Medication)
  • Unstable angina or myocardial infarction within 6 months of the trial
  • Unstable hypertension
  • Severe respiratory disease requiring continuous oxygen therapy
  • Indications Total gastrectomy
  • Borrmann type IV in the preoperative examination (including localized)
  • Suspected LN # 14v metastasis during surgery
  • Indications Pancreatectomy
  • Suspected a metastasis of CT scans LN # 13, LN # 14
  • Clinical stage IV group is suspected or confirmed during surgery

Exclusion

    Key Trial Info

    Start Date :

    August 6 2015

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2021

    Estimated Enrollment :

    518 Patients enrolled

    Trial Details

    Trial ID

    NCT03264807

    Start Date

    August 6 2015

    End Date

    December 31 2021

    Last Update

    March 3 2020

    Active Locations (12)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (12 locations)

    1

    The Catholic University of Korea, Incheon St. Mary'S Hospital

    Incheon, Bupyeong-gu, South Korea, 21431

    2

    Dongnam Inst. of Radiological & Medical Sciences

    Busan, Gijang-gun, South Korea, 46033

    3

    Gyeongsang national university hospital

    Gyeongsang, Gingu-si, South Korea, 52727

    4

    National Cancer Center

    Gyeonggi-do, Goyang-si, South Korea, 10408